In vivo screen identifies a SIK inhibitor that induces β cell proliferation through a transient UPR

It is known that beta cell proliferation expands the beta cell mass during development and under certain hyperglycemic conditions in the adult, a process that may be used for beta cell regeneration in diabetes. Here, through a new high-throughput screen using a luminescence ubiquitination-based cell cycle indicator (LUCCI) in zebrafish, we identify HG-9-91-01 as a driver of proliferation and confirm this effect in mouse and human beta cells. HG-9-91-01 is an inhibitor of salt-inducible kinases (SIKs), and overexpression of Sik1 specifically in beta cells blocks the effect of HG-9-91-01 on beta cell proliferation. Single-cell transcriptomic analyses of mouse beta cells demonstrate that HG-9-91-01 induces a wave of activating transcription factor (ATF)6-dependent unfolded protein response (UPR) before cell cycle entry. Importantly, the UPR wave is not associated with an increase in insulin expression. Additional mechanistic studies indicate that HG-9-91-01 induces multiple signalling effectors downstream of SIK inhibition, including CRTC1, CRTC2, ATF6, IRE1 and mTOR, which integrate to collectively drive beta cell proliferation. A high-throughput chemical screen identifies the salt-inducible kinase inhibitor HG-9-91-01 as a driver of beta cell proliferation, acting through an ATF6-dependent unfolded protein response.

Automated summary

A high-throughput chemical screen identified the salt-inducible kinase inhibitor HG-9-91-01 as a driver of beta cell proliferation, acting through an ATF6-dependent unfolded protein response. Mechanistic studies revealed that HG-9-91-01 induces multiple signaling effectors downstream of SIK inhibition, collectively driving beta cell proliferation.